Garrett added, "I want to welcome the talented people transferring to us from Dako. We see significant opportunities for Beckman Coulter in flow cytometry and continue to expand our investment in this fast-growing market segment."
The transaction is expected to close by the end of the year. More information about the transaction will be available during Beckman Coulter's 2007 Annual Business Review meeting on December 11. Contact Investor Relations for details.
About Dako
Dako, which is headquartered in Denmark, strives to improve tissue-based cancer diagnostics focusing on the workflow in the pathology laboratory. The company develops and markets instruments, reagents and software that will reduce time from biopsy to diagnosis, improve the quality and reliability of diagnosis, and increase efficiency in the lab. For information, visit http://www.dako.com.
About Beckman Coulter, Inc.
Based in Fullerton, California, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue consisting of supplies, test kits, service and operating-type lease payments represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit http://www.beckmancoulter.com.
Forward Looking Statements
This press release contains forward-looking statements, including
statements regarding the contribution of the acquisition to Beckman
Coulter's R&D and product development capabilit
'/>"/>
| SOURCE Beckman Coulter, Inc. Copyright©2007 PR Newswire. All rights reserved |